All Peptides
Semaglutide

Semaglutide

GLP-1 receptor agonist for significant weight loss

$349/mo

Virtual consult + lab work required

This peptide requires a brief virtual visit and recent bloodwork before our team can prescribe.

Details

Virtual Consult

Our licensed provider reviews your health profile via secure video — typically 10 minutes. Required for any peptide prescription.

Required Labs

  • Comprehensive Metabolic Panel (CMP)
  • Lipid Panel
  • HbA1c
  • Thyroid Panel (TSH, Free T3, Free T4)

Refund Policy: If found not eligible due to health reasons after consultation, you will receive a full refund.

Product Details

About Semaglutide

Mechanism of Action

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that activates the same receptors as the naturally occurring hormone GLP-1. When administered, it binds to GLP-1 receptors throughout the body, particularly in the pancreas, brain, and gastrointestinal tract. This activation triggers multiple physiological responses that work synergistically to promote weight loss and improve metabolic health.

Scientific Background

GLP-1 is an incretin hormone naturally released by the intestines in response to food intake. It plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. Semaglutide has a 94% structural similarity to human GLP-1 but includes modifications that extend its half-life to approximately one week, allowing for once-weekly dosing. The extended duration is achieved through albumin binding and resistance to degradation by the DPP-4 enzyme.

Clinical Applications

Originally developed for type 2 diabetes management, semaglutide gained FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Clinical trials have demonstrated average weight loss of 12-15% of body weight over 68 weeks, with additional benefits including improved cardiovascular outcomes, better glycemic control, and reduced inflammation markers. The medication is particularly effective when combined with lifestyle modifications including nutrition counseling and regular physical activity.

Evidence-Based

Clinical Research & Studies

Backed by peer-reviewed research from leading medical journals

2021
Peer Reviewed

STEP 1: A randomized controlled trial of weekly semaglutide in obesity

Participants receiving semaglutide 2.4mg achieved a mean weight loss of 14.9% compared to 2.4% with placebo over 68 weeks. The study demonstrated sustained weight reduction with improvements in cardiometabolic risk factors.

Read Full Study
2023
Peer Reviewed

SELECT: Semaglutide and cardiovascular outcomes in obesity

Semaglutide reduced the risk of major adverse cardiovascular events by 20% in patients with preexisting cardiovascular disease and overweight or obesity, independent of baseline diabetes status.

Read Full Study
2022
Peer Reviewed

STEP 5: Long-term efficacy and safety of semaglutide

Over 104 weeks, semaglutide demonstrated sustained weight loss of 15.2% with continued improvements in metabolic parameters and quality of life measures.

Read Full Study
Explore More

Related Resources

Similar Peptide Therapies

Tirzepatide
$449/mo

Tirzepatide

Dual GIP/GLP-1 agonist for enhanced fat loss

Learn More
Retatrutide
$549/mo

Retatrutide

Triple-action metabolic optimization

Learn More

Educational Articles

Article

Understanding GLP-1 Agonists: The Science Behind Weight Loss

Read Article
Article

Semaglutide vs Tirzepatide: Which is Right for You?

Read Article